Phase I Pharmacokinetic studies cannot reach their primary endpoints until bioanalytical data is confirmed as valid across the newly integrated organizational framework. The clinical research landscape shifted significantly with the announcement of Fortrea’s acquisition of Worldwide Clinical
Piramal Pharma is currently evaluating 38% of its critical suppliers against strict environmental, social, and governance criteria to ensure sustainability throughout the entire value chain. This initiative represents a fundamental shift in how the pharmaceutical industry approaches procurement,
Gland Pharma's Visakhapatnam Special Economic Zone Sterile Oncology Facility recently achieved a No Action Indicated status following a USFDA inspection with zero Form 483 observations. This significant regulatory outcome underscores the firm’s commitment to maintaining the highest quality
This digital initiative addresses long-standing inefficiencies by providing a public mechanism to verify the legal status of medical devices sold throughout the country. For many years, the Mexican medical device market struggled with a lack of transparency, where paper-based records led to
Maintaining medicinal consistency across a global network requires navigating a labyrinth of geopolitical shifts and varying international regulatory expectations. The journey of a pharmaceutical product from a manufacturing plant to a patient’s local pharmacy is an intricate operation governed by
Laboratories specializing in virology and immunology must now evaluate if their current biosafety margins are sufficient to protect staff from aerosolized H5N1 exposure. The recent isolation of live, infectious H5N1 avian influenza from a commercial batch of fetal bovine serum (FBS) has sparked a
